A real-world study of tafamidis in people with transthyretin amyloid cardiomyopathy (ATTR-CM) with heart and nerve symptoms: a plain language summary

Plain Language Summary: What is this summary about? This summary describes results from The Transthyretin Amyloidosis Outcomes Survey (THAOS for short). THAOS is a real-world study of people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM for short). Researchers looked at how tafamidis affects people with ATTR-CM who had both heart- and nerve-related symptoms. They calculated how long people lived and compared the data between those who took tafamidis and those who did not. They also compared how long and how often people had to stay in the hospital. Lastly, researchers looked at the side effects that people had during the study when they took tafamidis. What are the key takeaways? After two and a half years, a larger proportion of people who took tafamidis (82% or 82 in 100) were estimated to be alive than people who did not take tafamidis (75% or 75 in 100). On average, people who took tafamidis were hospitalized for heart-related problems less often than people who did not take tafamidis. People who took tafamidis also had shorter hospital stays for heart-related problems. The side effects people had when taking tafamidis were similar to those reported in previous clinical studies. What were the main conclusions reported by the researchers? The results from this real-world study suggest that people with ATTR-CM with heart- and nerve-related symptoms who take tafamidis may live longer with less frequent and shorter hospital stays for heart-related symptoms. Clinical trial number: NCT00628745.